NOV 17, 202659 MINS READ
Croscarmellose Sodium is synthesized through cross-linking reactions of carboxymethylcellulose sodium chains, yielding a three-dimensional hydrophilic polymer network with exceptional water uptake capacity 11. The cross-linked architecture imparts mechanical resilience while maintaining rapid swelling kinetics—a dual functionality essential for effervescent tablets that must withstand compaction forces yet disintegrate within seconds in aqueous environments. In effervescent formulations, CCS concentrations typically range from 2–6% w/w 1, significantly higher than conventional tablet applications, to counteract the hygroscopic nature of effervescent excipients (e.g., sodium bicarbonate, citric acid) and ensure consistent disintegration performance under variable humidity conditions.
The polymer's carboxylate functional groups (–COO⁻Na⁺) exhibit pH-dependent ionization, with maximum swelling occurring at pH 5–8 where electrostatic repulsion between anionic chains drives rapid water imbibition 3. This property proves advantageous in effervescent systems where CO₂ generation transiently lowers local pH; the subsequent pH rebound accelerates CCS swelling and tablet matrix disruption. Patent data demonstrate that CCS-containing effervescent tablets achieve >80% drug release within 10 minutes in 0.02N HCl at 37°C when CCS content exceeds 3% w/w 6, compared to 45–60% release for formulations using alternative disintegrants like sodium starch glycolate 2.
Key structural parameters influencing CCS performance in effervescent tablets include:
Comparative studies reveal that CCS outperforms crospovidone and sodium starch glycolate in effervescent matrices due to superior resistance to ionic strength effects—effervescent reactions generate high local concentrations of sodium ions (>0.5 M), which suppress swelling of non-cross-linked disintegrants but minimally affect CCS performance 2.
The disintegration mechanism of CCS in effervescent tablets involves synergistic interactions between polymer swelling and gas generation. Upon water contact, CCS particles rapidly imbibe water (swelling ratio 5–10× dry volume within 30 seconds 3), creating internal hydrostatic pressure that fractures the tablet matrix. Simultaneously, effervescent excipients undergo acid-base neutralization (e.g., NaHCO₃ + citric acid → sodium citrate + CO₂ + H₂O), generating CO₂ bubbles that propagate through CCS-induced microcracks and accelerate matrix disintegration.
Quantitative disintegration studies demonstrate concentration-dependent kinetics:
The optimal CCS concentration for effervescent tablets typically falls within 3–4% w/w, balancing rapid disintegration with adequate mechanical strength (hardness 60–100 N, friability <0.8%) 1. Patent formulations employing CCS at 3.5% w/w in combination with 400 mg sodium bicarbonate achieve 75% drug dissolution within 5 minutes and >90% within 10 minutes in simulated gastric fluid (pH 1.2, 37°C, 100 rpm paddle method) 10.
Advanced mechanistic insights from fluidized-bed coating studies reveal that CCS applied as an aqueous slurry (5–10% w/v) during granulation forms a continuous film around active pharmaceutical ingredient (API) particles, providing dual functionality as both a disintegrant and a taste-masking barrier 3. This approach proves particularly effective for bitter APIs (e.g., acetaminophen, ibuprofen), where CCS coatings at 8–12% w/w relative to API mass achieve >85% taste-masking efficacy in sensory panels while maintaining tablet disintegration times <60 seconds 4. The coating process requires precise control of inlet air temperature (50–60°C), spray rate (5–10 g/min), and atomization pressure (1.5–2.0 bar) to prevent CCS film cracking and ensure uniform coverage 3.
The distribution of CCS between intragranular (within granules) and extragranular (added post-granulation) phases critically influences disintegration performance. Patent formulations demonstrate that splitting CCS allocation—typically 60–70% intragranular and 30–40% extragranular—optimizes both granule integrity during drying and final tablet disintegration 1. Intragranular CCS (2–3% w/w) incorporated as an aqueous slurry during wet granulation coats API particles and promotes granule porosity, while extragranular CCS (1–2% w/w) blended with lubricants (e.g., magnesium stearate 0.5–1%) ensures rapid water penetration into the compressed tablet core 2.
Comparative dissolution profiles illustrate this effect:
For effervescent tablets containing water-soluble APIs (e.g., ascorbic acid, paracetamol), intragranular CCS content may be reduced to 1–2% w/w as API dissolution contributes to matrix disruption 1. Conversely, poorly soluble APIs (e.g., ibuprofen, naproxen) require higher intragranular CCS (3–4% w/w) to ensure adequate particle deaggregation and surface area exposure for dissolution 3.
Patent literature reveals that co-processed excipients combining microcrystalline cellulose (MCC), CCS, and calcium-sodium alginate complexes deliver superior performance in effervescent suspension tablets 1. A representative formulation comprises:
The alginate component undergoes ion exchange in aqueous media (Ca²⁺ → Na⁺), generating additional osmotic pressure that synergizes with CCS swelling. Tablets formulated with this ternary system achieve disintegration times of 35–50 seconds and form stable suspensions with <5% sedimentation after 5 minutes, suitable for pediatric and geriatric populations requiring liquid dosage forms 1. Compression forces of 8–12 kN yield tablets with hardness 80–100 N and friability <0.5%, meeting USP specifications for effervescent tablets 2.
Effervescent tablets face inherent stability challenges due to the hygroscopicity of acid-base excipients and the moisture sensitivity of CCS. Accelerated stability studies (40°C/75% RH, 6 months) demonstrate that CCS-containing effervescent formulations exhibit:
Mitigation strategies include:
Formulations incorporating these strategies demonstrate <10% change in disintegration time and <5% drug content variation after 24 months storage at 25°C/60% RH 5.
CCS enables development of taste-masked effervescent tablets through fluidized-bed coating of bitter APIs with CCS-binder-plasticizer films 3. A representative process involves:
Coated particles exhibit 10–15% weight gain and achieve 80–90% taste-masking efficacy in human sensory panels (n=15–20 subjects, paired comparison test) 4. When compressed into effervescent tablets (CCS-coated API 40%, sodium bicarbonate 30%, citric acid 15%, MCC 10%, flavoring 3%, lubricant 2%), the formulations disintegrate within 45–60 seconds and release >85% API within 10 minutes, with <15% subjects detecting bitterness 3. The CCS coating remains intact during tablet compression (8–10 kN force) but rapidly disintegrates upon water contact due to CO₂ bubble-induced mechanical disruption 4.
Counterintuitively, CCS can be incorporated into sustained-release effervescent systems through combination with hydrophilic polymers (e.g., hypromellose, hydroxypropyl cellulose) and hydrophobic bases (e.g., ethyl cellulose, glyceryl behenate) 7. A patented formulation comprises:
This system achieves biphasic release: rapid initial release (30–40% in first hour) driven by CCS disintegration and effervescence, followed by sustained release (remaining 60–70% over 6–12 hours) controlled by HPMC gel erosion 7. The formulation proves effective for drugs requiring both rapid onset (e.g., analgesics) and prolonged duration (e.g., anti-inflammatory agents), with in vivo studies demonstrating Tmax = 1.5–2 hours and therapeutic plasma levels maintained for 10–14 hours 9.
CCS plays a critical role in effervescent formulations of acid-labile proton pump inhibitors (PPIs) such as omeprazole and lansoprazole 10. These formulations employ high concentrations of sodium bicarbonate (≥400 mg per dose) to rapidly elevate gastric pH above 5, protecting the PPI from acid degradation during dissolution 10. CCS at 2–6% w/w ensures rapid tablet disintegration (<90 seconds) and uniform bicarbonate dispersion, achieving gastric pH >5 within 5 minutes of administration 12.
A representative omeprazole effervescent capsule formulation contains 10:
Upon capsule opening and dispersion in water, the immediate-release powder disintegrates within 30–45 seconds, rapidly neutralizing gastric acid, while the mini-tablets provide sustained omeprazole release over 4–6 hours 12. Clinical studies demonstrate 35–40% improvement in omeprazole bioavailability compared to enteric-coated tablets, attributed to reduced acid degradation and enhanced absorption in the neutral pH environment 10.
Systematic comparison of superdisintegrants in effervescent tablet formulations reveals distinct performance profiles 2:
**Croscarmellose Sodium (3–4% w/
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| FMC Corporation | Rapidly disintegrating effervescent suspension tablets for pediatric and geriatric populations requiring liquid dosage forms, suitable for both water-soluble and water-insoluble pharmaceuticals. | Ac-Di-Sol | Achieves tablet disintegration within 35-60 seconds when used at 3-6% w/w in effervescent suspension tablets, combined with microcrystalline cellulose and calcium-sodium alginate complex to form stable suspensions with less than 5% sedimentation after 5 minutes. |
| FMC Corporation | Taste-masked effervescent tablets for bitter active pharmaceutical ingredients such as acetaminophen and ibuprofen, particularly for pediatric applications requiring palatability and rapid dissolution. | Ac-Di-Sol Taste Masking System | Provides dual functionality as taste-masking coating (8-12% w/v aqueous slurry) and tablet disintegrant, achieving 80-90% taste-masking efficacy for bitter APIs while maintaining tablet disintegration times under 60 seconds in effervescent formulations. |
| Shionogi & Co. Ltd. | Extended-release effervescent systems for drugs requiring both rapid onset and prolonged therapeutic duration, such as analgesics and anti-inflammatory agents, enduring gastrointestinal peristaltic movement. | Sustained Release Effervescent Formulation | Enables biphasic drug release with 30-40% rapid initial release in first hour followed by sustained release over 6-12 hours when combined with hypromellose and magnesium oxide at 3-20% w/w croscarmellose sodium concentration. |
| Santarus Inc. | Acid-labile proton pump inhibitor delivery systems requiring immediate gastric pH neutralization to prevent drug degradation, suitable for treatment of gastroesophageal reflux disease and peptic ulcers. | Omeprazole Effervescent Capsule | Achieves gastric pH elevation above 5 within 5 minutes and 35-40% improvement in omeprazole bioavailability compared to enteric-coated tablets, using 2-6% w/w croscarmellose sodium with 400mg sodium bicarbonate for rapid disintegration under 90 seconds. |